Low Molecular Weight Heparin Induced Bullous Hemorrhagic Dermatosis
Thuillier D, Chaby G, Dadban A, Dascotte E, Miquel-Christophe O, Andrejak M, et al. Low-molecular-weight heparininduced bullous haemorrhagic dermatosis associated with cellmediated hypersensitivity. Ann Dermatol Venereol 2009 Oct;136(10):705-8.
Choudhary S, Fishman PM, Hernandez C. Heparin Induced Bullous Hemorrhagic Dermatosis. Cutis 2013;91:93-98.
Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990; 40:498-530.
Naveen KN, Rai V. Bullous Hemorrhagic Dermatosis: A Case Report. Indian J Dermatol 2014 Jul-Aug;59(4):423.
Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
Chang TW, Gharia M, Chiu YE. What Are These Hemorrhagic Crusts. Journal of Dermatologist;2012;20.
Schindewolf M Schwaner S, Wolter M. Incidence and causes of heparininduced skin lesions. CMAJ 2009;181:477-481.
Freedman MD. Pharmacodynamics, clinical indications, and adverse effects of heparin. J Clin Pharmacol 1992;32:584-596.
Batalla A, Roson E, Posada C, Florez A. Eosinophilic panniculitis after subcutaneous administration of sodium heparin. Indian J Dermatol Venereol Leprol 2013;79:849.
Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 1980;244:1209-1212.
- There are currently no refbacks.